Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 4Genitourinary 4Gastrointestinal 2Thoracic 1Head & Neck 1Classical hematology 1CNS 1

Conditions

Leukemia, Myeloid, Acute 191Anemia, Refractory, with Excess of Blasts 179Myelodysplastic Syndromes 175Leukemia 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Neoplasms 121Multiple Myeloma 116Venous Thromboembolism 111Anemia 108Leukemia, Myelomonocytic, Chronic 103Leukemia, Lymphocytic, Chronic, B-Cell 100Myeloproliferative Disorders 99Lymphoma, Non-Hodgkin 97Lymphoma 96Hodgkin Disease 85Thrombocytopenia 84Anemia, Aplastic 79Primary Myelofibrosis 67Lymphoma, Follicular 67Hematologic Neoplasms 63Leukemia, Myeloid, Chronic-Phase 61Lymphoma, Mantle-Cell 59Febrile Neutropenia 59Congenital Abnormalities 59Neoplasms, Plasma Cell 57Leukemia, Myeloid, Accelerated Phase 57Anemia, Refractory 57Leukemia, Myelogenous, Chronic, BCR-ABL Positive 56Blast Crisis 56Burkitt Lymphoma 53

Interventions

Darbepoetin alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Critical Illness × Classical hematology × Clear all
NCT00381836 2015-12-04

Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer

University of Aarhus

Phase 2/3 Terminated
140 enrolled
Classical hematologyGenitourinary

Anemia, Fatigue, Neoplasms, Prostatic Neoplasms, Critical Illness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡